Company Profile

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated,

research based, international pharmaceutical company, producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals and patients across
geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy
today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company
has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and
serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator
companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical
powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies,
globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it
will emerge stronger in terms of its global reach and in its capabilities in drug development
and manufacturing.

The company remains focused on ascending the value chain in the marketing of
pharmaceutical substances and is determined to bring in increased revenues from dosage
forms sales. Ranbaxy's robust performance in Cardiovascular, Central Nervous System,
Respiratory, Dermatology, Orthopaedic and Urology segments, clearly indicates that the
company has strengthened its presence in the fast growing chronic lifestyle disease segment.

Current Market Position

In June 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy from the family of CEO
and Managing Director Malvinder Mohan Singh for Rs. 10,000 crore (US$2.4 billion) at Rs.
737 per share. In November 2008, Daiichi-Sankyo completed the takeover of the company
from the founding Singh family in a deal worth $4.6 billion[dubious – discuss] by acquiring a
63.92% stake in Ranbaxy. Ranbaxy's Malvinder Singh remained as CEO after the
transaction. The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations,
with the combined company worth about US$30 billion.
On 7 April 2014 India based Sun Pharmaceutical and Japan based Daiichi Sankyo jointly
announced the sale of the entire 63.4% share from Daiichi Sankyo to Sun Pharmaceutical in a
$4 billion all-share deal. Under these agreements, shareholders of Ranbaxy, were to receive a
0.8 share of Sun Pharmaceutical for each share of Ranbaxy. After this acquisition, the
partner Daiichi-Sankyo was to hold a stake of 9% in Sun Pharmaceutical.
Organization Size

Before the acquisition by Sun pharmaceuticals, there were 10,983 employees working for
ranbaxy. Now Sun Pharmaceuticals employees 32,000 people.

Script